Acticor Biotech and the University of Birmingham in the UK have entered a collaboration to conduct a Phase IIb clinical trial of the new drug, glenzocimab, for the treatment of patients with myocardial infarction (MI) or heart attacks.

Named LIBERATE, the randomised, double-blind trial will evaluate the efficacy and tolerance of 1000mg of glenzocimab compared to a placebo for reducing heart damage following a heart attack.

The company intends to recruit over 200 subjects into the trial.

The trial will be carried out in two acute care hospitals in the country, namely the Queen Elizabeth Hospital, Birmingham, and the Northern General Hospital, Sheffield.

Glenzocimab’s ability to lower the amount of dead heart tissue in patients after an ST segment elevation myocardial infarction (STEMI), a serious type of heart attack, will be analysed.

A humanised monoclonal antibody (mAb) fragment directed against the platelet Glycoprotein VI (GPVI), glenzocimab is being evaluated for strokes.

Acticor Biotech developed the drug to treat cardiovascular emergencies including stroke. 

Glenzocimab prevents the activity of platelets that cause abnormal blood clotting. 

It could also potentially boost long-term outcomes in heart attack patients.

Acticor Biotech CEO and founder Gilles Avenard said: “Glenzocimab has already delivered very promising results in the treatment of acute ischemic stroke and we hope to confirm its therapeutics potential in another severe indication. 

“We are proud of this Phase IIb study launch, which allows glenzocimab development programme extension to myocardial infarction.”

In September this year, the company enrolled the first subject in the US in the Phase II/III ACTISAVE trial of glenzocimab to treat acute ischemic stroke.